Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
9.5.2023 09:00:00 EEST | Business Wire | Press release
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elite Tech, Accessible Price - Introducing the Logitech G3 Series Mouse and Keyboard for PC Gaming16.6.2026 10:05:00 EEST | Press release
Logitech G today announced the expansion of the G3 Series suite of PC Gaming products. Designed to bring pro-inspired performance to more gamers, the extended lineup features the G305 X SUPERLIGHT wireless gaming mouse and the G316 X 98 wired mechanical gaming keyboard. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616324864/en/ Logitech G today announced the expansion of the G3 Series suite of PC Gaming products. Designed to bring pro-inspired performance to more gamers, the extended lineup features the G305 X SUPERLIGHT wireless gaming mouse and the G316 X 98 wired mechanical gaming keyboard. These new products join the recently launched Logitech G325 gaming headset, completing the G3 series, a comprehensive high-performance desktop ecosystem that delivers excellent performance, world-class features, and unique customization at an affordable price point. “By fusing elite precision, like our sub-micron HERO 44K sensor a
Eurooppalaisia yrityksiä uhkaa "näkyvyyskuilu", kun tekoäly määrittelee hakua ja asiakashankintaa uudelleen16.6.2026 10:00:00 EEST | Tiedote
Eurooppalaisilla yrityksillä on aiempaa vaikeampaa tavoittaa asiakkaita verkossa, ja ne kamppailevat epäselvyyden kanssa siitä, mikä ajaa kasvua. Näin kertoo digitaalinen ekosysteemipalveluntarjoaja team.bluen ensimmäinen vuotuinen Euroopan liiketoiminnan tila -raportti. Yli 10 000 yritykseltä 32 maassa tehty tutkimus varoittaa kasvavasta "näkyvyyskuilusta" eurooppalaisille yrityksille – syvenevästi katkoksesta heidän verkkonäkyvyytensä ja kyvykkyytensä välillä ymmärtää, vaikuttaa ja mitata sitä, miten asiakkaat löytävät heidät. Asiakashankintamaailma muuttuu nopeammin kuin useimmat yritykset ehtivät sopeutua: lähes joka kolmas yritys (30,6 %) raportoi, että asiakkaiden tavoittaminen verkossa on vaikeutunut viimeisen kahden vuoden aikana. Löytämisen kenttä on samanaikaisesti rikkaampi ja pirstaloituneempi kuin koskaan ennen – dynamiikka, jonka team.blue on nimennyt "Näkyvyystaloudeksi" (Visibility Economy). Yritysten luottamus siihen, miten asiakkaat löytävät heidät, on heikentynyt Kun
Tampere Philharmonic Orchestra Appoints Kristian Sallinen as the Next Chief Conductor16.6.2026 10:00:00 EEST | Press release
Kristian Sallinen has been appointed Chief Conductor and Artistic Director of the Tampere Philharmonic Orchestra. He will begin his three-year term in August 2027, following the tenure of British conductor Matthew Halls. Sallinen will conduct a minimum of 7–8 programmes each season alongside other projects and will become the thirteenth Chief Conductor in the Finnish orchestra’s 96-year history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615800659/en/ Conductor Kristian Sallinen will begin his tenure as the new Chief Conductor of the Tampere Philharmonic Orchestra in August 2027. Photo: Antti Rintala. Sallinen last appeared in Tampere in September 2025, conducting Richard Strauss’s Der Rosenkavalier Suite and Magnus Lindberg’s Concerto for Orchestra. He will return this September to lead a programme of Finnish music by Jean Sibelius, Kaija Saariaho and Väinö Raitio. – I am deeply honoured and grateful for the trust th
ABB Robotics and PSYONIC Use Human-Generated Data to Advance Robotic Dexterity16.6.2026 07:01:00 EEST | Press release
ABB Robotics is collaborating with California bionics company, PSYONIC, to advance robotic gripping and dexterity using a new approach that utilizes real-world manipulation data from human prosthetic use. By combining the PSYONIC Ability Hand with an ABB GoFa™ cobot, the collaboration will explore how touch and motion data generated by human prosthetic use can be used to train robots to perform delicate, variable tasks that have traditionally been difficult to automate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612749544/en/ “Human dexterity and the instinctive understanding of how to handle different objects is one of the most difficult things to replicate in industrial-grade robotics, but it’s a fundamental need for truly autonomous and versatile robots,” said Marc Segura, President, ABB Robotics. “As we develop the next generation physical AI, robots will learn and understand the world as we do. This collaboration
Signaloid Announces Availability of Amazon AWS Machine Image (AMI) for Accelerating Compute Workloads Ranging from Finance to Reinforcement Learning16.6.2026 07:00:00 EEST | Press release
British computing technology company Signaloid today announced the release of the Signaloid Compute Engine Amazon Machine Image (AMI) via AWS Marketplace. The release enables organizations to deploy Signaloid’s distribution-extended compute hardware (UxHw®) technology within their Amazon Virtual Private Clouds (VPCs). The AMI provides access to UxHw, which delivers orders-of-magnitude performance improvements on x86_64 and ARM (AArch64) AWS Elastic Compute Cloud (EC2) instances. Without requiring software rewrites, UxHw enables existing applications to compute directly on probability distributions, automating algorithms such as Monte Carlo methods in finance and physics, importance sampling in reinforcement learning, and particle filters in physical AI and robotics. The technology works through binary translation and optimization at the LLVM intermediate representation (LLVM IR) level, with optional hardware acceleration via FPGAs and Signaloid’s C0-ASIC that was recently taped-out in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom